Ovarian Cancer Therapy Trial Showed Patient Progress
A clinical trial at Moffitt Cancer Center has reported positive outcomes for patients with recurrent ovarian cancer.
Updated on Oct. 5, 2026 in Cancer
Researchers have observed stable disease for three months in a recurrent ovarian cancer patient treated with the experimental therapy lira-cel. The phase 1 trial in Tampa has also seen multiple participants survive more than one year following treatment.
Why it matters
This study aims to determine the maximum tolerated dose of the therapy to better address recurrent gynecological cancers. Early indications of stability and survival suggest the potential for this treatment approach to offer new options for patients with limited choices.
The study, which has an estimated enrollment of 10 patients, observed three months of stable disease at the highest dose level of 1 x 10⁷ cells/kg. Multiple patients have survived more than one year, with one individual surviving over two years.
The players
Moffitt Cancer Center
This is a prominent cancer research institution located in Tampa that conducts various clinical trials for oncology patients.
The details
The lira-cel therapy is administered directly into the peritoneal cavity to target recurrent ovarian, fallopian tube, or primary peritoneal cancer. No dose-limiting toxicities have been observed as investigators continue to treat patients in escalating dose cohorts.
Timeline
October 5, 2026: The stable disease case was officially announced.
The Big Picture
This research follows the ongoing protocols established by the clinical trial NCT05316129, which is currently testing the efficacy of cell-based therapies in aggressive gynecological cancers.
While this trial provides insight into the potential efficacy of lira-cel, the study is currently in its early phase and not yet an available standard treatment. Patients interested in experimental options should discuss clinical trial eligibility and specific side effects with their oncology team.
The takeaway
These early results provide a foundation for future larger-scale trials by establishing the safety of current dose cohorts. Patients and their families are encouraged to monitor ongoing trial updates as investigators continue to evaluate the long-term potential of this therapy.
Further reading
For additional context on current research in this field, visit the Cancer section.
More information
View the full clinical trial registration details for more information on the study design and enrollment criteria.
